Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Signs CRADA With US Army to Develop RNAi-Based Antivirals

NEW YORK, April 13 (GenomeWeb News) - Alnylam Pharmaceuticals and the United States Army Medical Research Institute of Infectious Diseases plan to co-develop RNAi therapeutics targeting viruses, Alnylam said yesterday.


Under the Cooperative Research and Development Agreement, Alnylam will use its RNAi therapeutic platform to discover and develop agents against viruses posing "a serious biological threat to the military and public health," including hemorrhagic fever viruses, according to a company statement.


According to Alnylam, USAMRIID is "an organization which is uniquely positioned to collaborate in translational research for Biosafety Level 4 threats."


Last year, Alnylam signed a CRADA with the Department of Defense's DARPA unit to develop RNAi-based influenza therapeutics.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.